GenNBio

GenNBio is a South Korean biotechnology company specializing in xenotransplantation and regenerative medicine to address the global shortage of human donor organs. The company utilizes gene-edited, pathogen-free pigs to develop bio-artificial organs and tissues, including pancreatic islets, corneas, and kidneys. Its lead program, involving the transplantation of porcine pancreatic islets for type 1 diabetes, has advanced into Phase 1 clinical trials in collaboration with major medical centers. Beyond organ development, GenNBio also focuses on immunosuppressive therapies and medical devices designed to support successful transplantation outcomes. The company operates a specialized manufacturing facility for xenotransplantation products and maintains strategic partnerships with gene-editing and pharmaceutical leaders.